Mycobacterium Bovis-BCG Vaccination Induces Specific Pulmonary Transcriptome Biosignatures in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Jul 3

PMID 20596522

Citations 21

Authors

Elihu Aranday Cortes

Daryan Kaveh

Javier Nunez-Garcia

Philip J Hogarth

H Martin Vordermeier

Affiliations

Soon will be listed here.

Abstract

Background: In the present study, we applied microarray technology to define biosignatures by microarray transcriptome analysis in lung and spleen samples after BCG vaccination and M. bovis infection of BALB/c mice. The aims were two-fold, namely to define biosignatures that could predict vaccine success before challenge, and biomarker patterns that correlated with anamnestic protective responses following exposure to virulent M. bovis. Further, these biosignatures should be detectable without in vitro antigenic challenge.

Principal Findings: After BCG vaccination, we defined a specific pulmonary gene expression signature related to the connective tissue development and function network that predicted vaccine success before M. bovis challenge. In addition, a Th17-related cytokine profile was found that correlated with vaccine-induced protective immunity following infection with virulent M. bovis in the lung as well as additional genes that were up-regulated in the spleens of vaccinated animals post-infection related to neutrophil biology and inflammation.

Conclusions: This study has therefore prioritized both biomarkers predicting vaccination success before challenge and bio-signatures that are potentially associated with protective immune responses that will be useful to evaluate future vaccine candidates.

Citing Articles

The Cellular and Transcriptomic Early Innate Immune Response to BCG Vaccination in Mice.

Kondratyeva L, Rakitina O, Pleshkan V, Kuzmich A, Linge I, Kondratieva S Cells. 2025; 13(24.

PMID: 39768135 PMC: 11674076. DOI: 10.3390/cells13242043.

Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent.

Painter H, Larsen S, Williams B, Abdelaal H, Baldwin S, Fletcher H mSphere. 2024; 10(1):e0086424.

PMID: 39651886 PMC: 11774039. DOI: 10.1128/msphere.00864-24.

Transcriptional signatures measured in whole blood correlate with protection against tuberculosis in inbred and outbred mice.

Kurtz S, Ryden P, Elkins K PLoS One. 2023; 18(8):e0289358.

PMID: 37535648 PMC: 10399789. DOI: 10.1371/journal.pone.0289358.

A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.

Singh S, Saavedra-Avila N, Tiwari S, Porcelli S Front Immunol. 2022; 13:959656.

PMID: 36091032 PMC: 9459386. DOI: 10.3389/fimmu.2022.959656.

Contribution and Future of High-Throughput Transcriptomics in Battling Tuberculosis.

Martinez-Perez A, Estevez O, Gonzalez-Fernandez A Front Microbiol. 2022; 13:835620.

PMID: 35283833 PMC: 8908424. DOI: 10.3389/fmicb.2022.835620.

References

Border W, Noble N, Yamamoto T, Harper J, Yamaguchi Y, Pierschbacher M . Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992; 360(6402):361-4. DOI: 10.1038/360361a0. View

Elkington P, Friedland J . Matrix metalloproteinases in destructive pulmonary pathology. Thorax. 2005; 61(3):259-66. PMC: 2080735. DOI: 10.1136/thx.2005.051979. View

Izzo A, Izzo L, Kasimos J, Majka S . A matrix metalloproteinase inhibitor promotes granuloma formation during the early phase of Mycobacterium tuberculosis pulmonary infection. Tuberculosis (Edinb). 2004; 84(6):387-96. DOI: 10.1016/j.tube.2004.07.001. View

Burster T, Macmillan H, Hou T, Boehm B, Mellins E . Cathepsin G: roles in antigen presentation and beyond. Mol Immunol. 2009; 47(4):658-65. PMC: 4159238. DOI: 10.1016/j.molimm.2009.10.003. View

Wielockx B, Libert C, Wilson C . Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?. Cytokine Growth Factor Rev. 2004; 15(2-3):111-5. DOI: 10.1016/j.cytogfr.2003.12.001. View

Appelberg R, Silva M . T cell-dependent chronic neutrophilia during mycobacterial infections. Clin Exp Immunol. 1989; 78(3):478-83. PMC: 1534828. View

Skinner M, Wedlock D, Buddle B . Vaccination of animals against Mycobacterium bovis. Rev Sci Tech. 2001; 20(1):112-32. DOI: 10.20506/rst.20.1.1276. View

Hoshino A, Nagao T, Nagi-Miura N, Ohno N, Yasuhara M, Yamamoto K . MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner. J Autoimmun. 2008; 31(1):79-89. DOI: 10.1016/j.jaut.2008.03.006. View

Rodgers A, Whitmore K, Walker K . Potential correlates of BCG induced protection against tuberculosis detected in a mouse aerosol model using gene expression profiling. Tuberculosis (Edinb). 2006; 86(3-4):255-62. DOI: 10.1016/j.tube.2006.01.020. View

10.

Volkman H, Pozos T, Zheng J, Davis J, Rawls J, Ramakrishnan L . Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science. 2009; 327(5964):466-9. PMC: 3125975. DOI: 10.1126/science.1179663. View

11.

Plager D, Loegering D, Checkel J, Tang J, Kephart G, Caffes P . Major basic protein homolog (MBP2): a specific human eosinophil marker. J Immunol. 2006; 177(10):7340-5. DOI: 10.4049/jimmunol.177.10.7340. View

12.

He X, Han B, Liu M . Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2007; 292(5):L1039-49. DOI: 10.1152/ajplung.00490.2006. View

13.

Kolibab K, Yang A, Derrick S, Waldmann T, Perera L, Morris S . Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol. 2010; 17(5):793-801. PMC: 2863387. DOI: 10.1128/CVI.00006-10. View

14.

Lyons M, Yoshimura T, McMurray D . Mycobacterium bovis BCG vaccination augments interleukin-8 mRNA expression and protein production in guinea pig alveolar macrophages infected with Mycobacterium tuberculosis. Infect Immun. 2002; 70(10):5471-8. PMC: 128323. DOI: 10.1128/IAI.70.10.5471-5478.2002. View

15.

Gaucher D, Therrien R, Kettaf N, Angermann B, Boucher G, Filali-Mouhim A . Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008; 205(13):3119-31. PMC: 2605227. DOI: 10.1084/jem.20082292. View

16.

Khader S, Cooper A . IL-23 and IL-17 in tuberculosis. Cytokine. 2008; 41(2):79-83. PMC: 2266085. DOI: 10.1016/j.cyto.2007.11.022. View

17.

Sheen P, OKane C, Chaudhary K, Tovar M, Santillan C, Sosa J . High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J. 2008; 33(1):134-41. DOI: 10.1183/09031936.00127807. View

18.

Hogarth P, Logan K, Vordermeier H, Singh M, Hewinson R, Chambers M . Protective immunity against Mycobacterium bovis induced by vaccination with Rv3109c--a member of the esat-6 gene family. Vaccine. 2005; 23(20):2557-64. DOI: 10.1016/j.vaccine.2004.11.030. View

19.

Augustine C, Yoo J, Potti A, Yoshimoto Y, Zipfel P, Friedman H . Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009; 15(2):502-10. DOI: 10.1158/1078-0432.CCR-08-1916. View

20.

Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L . TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins. Blood. 2008; 113(14):3235-44. DOI: 10.1182/blood-2008-07-166595. View